GE warns over anesthesia devices; Medtronic, RTI unite on spinal implants;

@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev

> GE Healthcare ($GE) is warning customers that some of its anesthesia delivery systems can malfunction, leading to higher-than-expected dosing. News

> MDxHealth plans to expand its PredictMDx brain tumor test in the U.S. now that the diagnostic has been included in the guidelines of the National Comprehensive Cancer Network. More

> RTI ($RTIX) has signed a deal with Medtronic ($MDT) to distribute allograft implants for use in spinal surgeries. Announcement

> Australia's Osprey Medical is raising about $13.4 million through a private placement to support its FDA-cleared interventional cardiology device. Release

> Device incubator Inceptus Medical has raised $4.7 million to launch its first company, the cardiovascular-focused Inari Medical. Item

Biotech News

@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech

@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce

@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce

@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce

> Is Eli Lilly about to start cutting its blockbuster R&D budget? More

> MedImmune leads $12.5M round for new drug aimed at big chemo market. Article

> Sanofi, Regeneron take the lead in blockbuster PhIII race of PCSK9 drugs. Story

Pharma News

@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce

> Sanofi invests in Fabrazyme production as sales soar. Report

> Teva halts Israeli layoff plans amid pressure from labor, government. Article

> Telegraph: GlaxoSmithKline's ex-China chief barred from leaving country. Story

Biomarkers News

> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article

> Amgen taps KineMed for Alzheimer's biomarkers. Report

> Skin may conceal a viable Parkinson's biomarker. Story

Drug Delivery News

@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce

> Mini-pancreas grown from stem cells has implications for future insulin delivery. More

> Cell membrane models 'written' on graphene provide drug-delivery model. Item

> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article

> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story

Diagnostics News

@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce

> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More

> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report

> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story

> New blood test screens for irritable bowel syndrome. Article

> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.